Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio is a rapidly growing company with a portfolio of innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of a patient's anatomy. With a strong focus on leveraging the body's natural healing response and minimizing long-term exposure to permanent synthetic materials, TELA Bio is well-positioned to succeed in the hernia repair and abdominal wall reconstruction market. While there are potential risks associated with government regulation and pending litigation, TELA Bio's track record of gaining regulatory approvals and its dedication to enhancing patient outcomes make it a promising investment.

Bears say

TELA Bio is focused on providing soft-tissue reconstruction solutions, but negative analyst sentiment stems from concerns about execution and conservative guidance. Their sales team reorganization and new hires give some hope for improvement in the second half of the year, but the company still has a lot of work to do. The lowered sales outlook and continued losses also contribute to a negative outlook, as does the concentrated product portfolio and reliance on reimbursement rates.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.